^
BIOMARKER:

PIK3CA mutation + HR positive

i
Other names: PIK3CA, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, Phosphoinositide-3-kinase, catalytic, alpha polypeptide, Serine/threonine protein kinase PIK3CA, PtdIns-3-kinase subunit P110-alpha, PI3K-alpha, Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 KDa catalytic subunit alpha, Phosphatidylinositol 3-kinase, Catalytic, 110-KD, alpha, PI3-kinase P110 subunit alpha, PI3-kinase subunit alpha, PtdIns-3-kinase subunit alpha, PI3Kalpha, P110alpha, PI3K, ESR1, Era, ESR, NR3A1
Entrez ID:
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
alpelisib
Sensitive: A1 - Approval
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
CDK6 inhibitor + alpelisib
Sensitive: A2 - Guideline
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
CDK4 inhibitor + alpelisib
Sensitive: A2 - Guideline
PIK3CA mutation + HR positive
Hormone Receptor Positive Breast Cancer
alpelisib
Sensitive: C1 - Off-label
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
GDC-0077
Sensitive: C2 – Inclusion Criteria
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
palbociclib + GDC-0077
Sensitive: C3 – Early Trials
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
alpelisib + GDC-0032
Sensitive: C3 – Early Trials
PIK3CA mutation + HR positive
HER2 Positive Breast Cancer
trastuzumab
Resistant: C3 – Early Trials
PIK3CA mutation + HR positive
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
CDK4 inhibitor
Resistant: C3 – Early Trials
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
CDK6 inhibitor
Resistant: C3 – Early Trials